Capricor Therapeutics, Inc. (NasdaqGS: CAPR)
Health Care · Biotechnology · US
$8.29
+21.91% today · +25.6% 1Y
Capricor Therapeutics, Inc. (NasdaqGS: CAPR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $481.97M and employs 231 people.
Over the last twelve months the share price has gained 25.6%, trading between 2.96 and 40.37.
Tweenvest scores Capricor Therapeutics, Inc. across four factors: quality 28/100. Its strongest factor is quality.
CAPR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $481.97M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.47
- Dividend yield
- —
- Beta (5Y)
- 0.53
- 52-week high
- $40.37
- 52-week low
- $2.96
- Avg volume (3M)
- —
- Shares outstanding
- 58.14M
- Employees
- 231
- Next earnings
- —
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
- ISIN
- US14070B3096
- Founded
- 2005
- Listed since
- Feb 13, 2007
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.